Publications by authors named "Saber A Amin"
To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis. Survival outcome was compared between groups with immunotherapy and groups without immunotherapy. Chemoimmunotherapy was associated with improved OS (hazard ratio [HR] 0.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed the demographic and clinical factors influencing the use of targeted therapies in first-line treatment for ovarian cancer patients diagnosed between 2012 and 2019.
- Out of 99,286 patients, only 4.1% received targeted therapy, with notable racial disparities where non-Hispanic Black women had lower rates compared to non-Hispanic White women.
- Various factors, including age, cancer stage, comorbid conditions, healthcare access, and type of chemotherapy received, were linked to differences in the likelihood of receiving targeted therapy.
Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?
Cancer Epidemiol Biomarkers Prev
February 2023
Background: We investigated racial and ethnic disparities in treatment sequence [i.e., neoadjuvant chemotherapy (NACT) plus interval debulking surgery (IDS) versus primary debulking surgery (PDS) plus adjuvant chemotherapy] among patients with ovarian cancer and its contribution to disparities in mortality.
View Article and Find Full Text PDFImmunotherapy has been approved for stage III non-small cell lung cancer (NSCLC) as consolidation therapy after chemoradiation in patients whose disease does not progress after chemoradiation. However, many patients do not receive chemoradiation due to either the drugs' side effects or poor performance status. This study's objective is to investigate the association of immunotherapy combined with chemotherapy or Radiotherapy (RT) with the overall survival (OS) of stage III NSCLC patients who do not receive chemoradiation.
View Article and Find Full Text PDFBackground And Purpose: Stereotactic Body Radiotherapy (SBRT) has emerged as a standard treatment for inoperable early-stage non-small cell lung cancer (NSCLC) with remarkable local control. However, it is not clear if this local control translates to overall survival (OS). The objective of this study is to investigate the impact of SBRT on the OS of early-stage NSCLC patients and examine if the extent of this impact changes with the era of diagnosis, T stage, age, and comorbidity status.
View Article and Find Full Text PDF